免疫抑制剂免疫调节的窗口：受者向雷帕霉素的转化增加了潜在的耐受免疫细胞。

A window into immunosuppressant immunoregulation: recipient conversion to rapamycin increases potentially tolerogenic immune cells.

机构信息

1] Starzl Transplantation Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA [2] Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA [3] Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

1] Institute for Clinical Immunology and Transfusion Medicine, Justus Liebig University, Giessen, Germany [2] University Hospital Giessen and Marburg, Giessen, Germany.

出版信息

Kidney Int. 2014 Apr;85(4):743-5. doi: 10.1038/ki.2013.420.

DOI:10.1038/ki.2013.420

PMID:24682122

Abstract

Mechanistic target of rapamycin inhibitors (mTORi) have a complex immunoregulatory profile in both animal models and transplant patients. Studies suggest that mTORi act as tolerance-supporting and regulatory T cell (Treg)-promoting immunosuppressants. Yet proinflammatory influences on myeloid dendritic cells have been established. Insight is needed into the impact of mTORi on immune cells. Stallone et al. describe a clinical study identifying a potential immunoregulatory pathway involving plasmacytoid dendritic cells and Tregs in renal transplant patients on mTORi.

摘要

雷帕霉素靶蛋白抑制剂（mTORi）在动物模型和移植患者中具有复杂的免疫调节作用。研究表明，mTORi 作为耐受支持和调节性 T 细胞（Treg）促进的免疫抑制剂发挥作用。然而，已经确定了对髓样树突状细胞的促炎影响。需要深入了解 mTORi 对免疫细胞的影响。Stallone 等人描述了一项临床研究，该研究确定了一种潜在的免疫调节途径，涉及接受 mTORi 的肾移植患者中的浆细胞样树突状细胞和 Treg。